Table of Contents PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT PART 03: RESEARCH METHODOLOGY PART 04: INTRODUCTION • Market outline PART 05: MARKET LANDSCAPE • Market size and forecast • Five forces analysis PART 06: MARKET SEGMENTATION BY END-USER • Comparison by end-user • Biotechnology • Pharmaceutical • Market opportunity by end-user PART 07: REGIONAL LANDSCAPE • Regional comparison • Nanoparticles market in biotechnology and pharmaceutical sectors in Americas • Nanoparticles market in biotechnology and pharmaceutical sectors in EMEA • Nanoparticles market in biotechnology and pharmaceutical sectors in APAC • Market opportunity PART 08: DECISION FRAMEWORK PART 09: DRIVERS AND CHALLENGES • Market drivers • Market challenges PART 10: MARKET TRENDS • Increasing demand for nanoparticles in stem cell therapy • Increasing prevalence of chronic diseases • Increasing use of gold nanoparticles PART 11: VENDOR LANDSCAPE • Competitive scenario • Investment opportunity PART 12: VENDOR ANALYSIS • Vendor overview • Merck • F. Hoffmann-La Roche • GE Healthcare • Novartis • Other prominent vendors PART 13: APPENDIX • List of abbreviations List of Exhibits Exhibit 01: Applications of nanoparticles in biotechnology and pharmaceutical sectors Exhibit 02: Detection of cancer cells in bloodstream through use of nanoparticles Exhibit 03: Global nanoparticles market in biotechnology and pharmaceutical sectors: Market overview Exhibit 04: Global nanoparticles market in biotechnology and pharmaceutical sectors 2016-2021 ($ billions) Exhibit 05: Five forces analysis Exhibit 06: Global nanoparticles market in biotechnology and pharmaceutical sectors by end-user 2016-2021 (% share) Exhibit 07: Comparison by end-user Exhibit 08: Global nanoparticles market by biotechnology 2016-2021 ($ billions) Exhibit 09: Global nanoparticles market by biotechnology – Year over year growth Exhibit 10: Global nanoparticles market by pharmaceutical 2016-2021 ($ billions) Exhibit 11: Nanoparticles in pharmaceuticals Exhibit 12: Global nanoparticles market by pharmaceutical – Year over year growth Exhibit 13: Global nanoparticles market in biotechnology and pharmaceutical sectors by region 2016-2021 (% share) Exhibit 14: Regional comparison Exhibit 15: Nanoparticles market in biotechnology and pharmaceutical sectors in Americas 2016-2021 ($ billions) Exhibit 16: Nanoparticles market in biotechnology and pharmaceutical sectors in Americas – Year over year growth Exhibit 17: Top 3 countries in Americas Exhibit 18: Nanoparticles market in biotechnology and pharmaceutical sectors in EMEA 2016-2021 ($ billions) Exhibit 19: Nanoparticles market in biotechnology and pharmaceutical sectors in EMEA – Year over year growth Exhibit 20: Top 3 countries in EMEA Exhibit 21: Nanoparticles market in biotechnology and pharmaceutical sectors in APAC 2016-2021 ($ billions) Exhibit 22: Nanoparticles market in biotechnology and pharmaceutical sectors in APAC – Year over year growth Exhibit 23: Top 3 countries in APAC Exhibit 24: Nanoparticle-based products under clinical trials Exhibit 25: Major chronic disease-related deaths 2012 (in thousands) Exhibit 26: Strategic success factors for vendors to consider Exhibit 27: Investment opportunity mapping Exhibit 28: Merck: Profile Exhibit 29: Merck: Strength analysis Exhibit 30: Merck: Strategy assessment Exhibit 31: Merck: Opportunity assessment Exhibit 32: F. Hoffmann-La Roche: Profile Exhibit 33: F. Hoffmann-La Roche: Strength analysis Exhibit 34: F. Hoffmann-La Roche: Strategy assessment Exhibit 35: F. Hoffmann-La Roche: Opportunity assessment Exhibit 36: GE Healthcare: Profile Exhibit 37: GE Healthcare: Strength analysis Exhibit 38: GE Healthcare: Strategy assessment Exhibit 39: GE Healthcare: Opportunity assessment Exhibit 40: Novartis: Profile Exhibit 41: Novartis: Strength analysis Exhibit 42: Novartis: Strategy assessment Exhibit 43: Novartis: Opportunity assessment

F. Hoffmann-La Roche, GE Healthcare, Merck, Novartis, AMAG Pharmaceuticals, Amgen, Bausch & Lomb, Biogen, Celgene, Gilead, Ipsen, Leadiant Biosciences, nanoComposix, Pacira Pharmaceuticals, Pfizer, Shire, and UCB.